Overview

Webcast ImageWebcast
MannKind at Bank of America Merrill Lynch Health Care Conference (Replay)
05/15/12 at 10:40 a.m. PT

MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

Featured Links


Receive E-mail AlertsE-mail Alert Icon
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!
MNKD (Common Stock)
ExchangeNASDAQ GM (US Dollar)
Price$1.83
Change (%) Stock is Up 0.02 (1.10%)
Volume1,923,000
Data as of 05/16/12 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore Press Releases
DateTitle 
05/09/12MannKind Corporation Reports 2012 First Quarter Financial Results
- Conference Call to Begin Today at 5:00 PM EDT - VALENCIA, Calif.--(BUSINESS WIRE)--May. 9, 2012-- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the first quarter ended March 31, 2012. For the first quarter of 2012, total operating expenses were $33.9 million, compared to $38.1 million for the first quarter of 2011, a decrease of $4.1 million. Research and development (R&D) expenses were ... 
Printer Friendly Version
05/08/12MannKind to Present at Bank of America Merrill Lynch 2012 Health Care Conference
VALENCIA, Calif.--(BUSINESS WIRE)--May. 8, 2012-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday, May 15, 2012 at 10:40 am Pacific Daylight Time at the Encore at the Wynn in Las Vegas, Nevada. Interested parties can access a link to the live webcast of... 
Printer Friendly Version
05/02/12MannKind Corporation to Hold 2012 First Quarter Financial Results Conference Call on May 9, 2012
VALENCIA, Calif.--(BUSINESS WIRE)--May. 2, 2012-- MannKind Corporation (Nasdaq: MNKD) will release its 2012 first quarter financial results on Wednesday, May 9, 2012 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 5:00 PM (Eastern Time) on May 9, 2012. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann, President and C... 
Printer Friendly Version
04/30/12Tolero and MannKind Sign Collaboration and License Agreement to Develop and Commercialize Novel BTK Inhibitors for Hematological Malignancies and Inflammatory Diseases
SALT LAKE CITY & VALENCIA, Calif.--(BUSINESS WIRE)--Apr. 30, 2012-- Tolero Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of novel therapeutics to treat cancer and other serious human diseases, and MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes and cancer, today announced a license agreement granting Tolero exclusive worldwide rig... 
Printer Friendly Version
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.



Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet